BIOMAT Database Logo BIOMAT Database Logo

A comparative immunohistochemical study of phaeochromocytomas and paragangliomas. 1993

M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
Department of Anatomy and Forensic Sciences, General Hospital of Galicia-School of Medicine, University of Santiago, Spain.

There is no definite morphological distinction between phaeochromocytomas and paragangliomas. We, therefore, attempted to determine the universality and differential utility of a panel of tumour markers for diagnosis in formalin-fixed, paraffin-embedded specimens. Antibodies to neuron-specific enolase (NSE), chromogranin, synaptophysin, Leu-7, neurofilaments, cytokeratins, carcinoembryonic antigen (CEA), melanoma antigen HMB-45, S-100 protein and glial fibrillary acid protein (GFAP), were used on 11 phaeochromocytomas and 8 paragangliomas. NSE reactivity was detected in 10 phaeochromocytomas and in all paragangliomas. Chromogranin reactivity was found in all but two cases (one phaeochromocytoma and one paraganglioma). Synaptophysin reactivity was present in 10 phaeochromocytomas and in the 8 paragangliomas. Ten phaeochromocytomas stained for Leu-7, but none of the paragangliomas did. S-100-positive cells (sustentacular or type II cells) were found in 8 phaeochromocytomas and 7 paragangliomas. GFAP stained sustentacular cells of only one paraganglioma. Only in 5 phaeochromocytomas was there a focal reaction by neurofilaments. Cytokeratins, CEA and HMB-45 were never detected. We conclude that NSE, chromogranin, synaptophysin and S-100 protein are useful markers of both types of tumour, whereas GFAP staining is limited to a small number of these neoplasms. Leu-7 reactivity seems to favour diagnosis of phaeochromocytoma rather than paraganglioma, but further studies with larger series are needed to confirm this. Unlike previous reports, we did not find cytokeratin or HMB-45 immunostaining in any case.

UI MeSH Term Description Entries
D007150 Immunohistochemistry Histochemical localization of immunoreactive substances using labeled antibodies as reagents. Immunocytochemistry,Immunogold Techniques,Immunogold-Silver Techniques,Immunohistocytochemistry,Immunolabeling Techniques,Immunogold Technics,Immunogold-Silver Technics,Immunolabeling Technics,Immunogold Silver Technics,Immunogold Silver Techniques,Immunogold Technic,Immunogold Technique,Immunogold-Silver Technic,Immunogold-Silver Technique,Immunolabeling Technic,Immunolabeling Technique,Technic, Immunogold,Technic, Immunogold-Silver,Technic, Immunolabeling,Technics, Immunogold,Technics, Immunogold-Silver,Technics, Immunolabeling,Technique, Immunogold,Technique, Immunogold-Silver,Technique, Immunolabeling,Techniques, Immunogold,Techniques, Immunogold-Silver,Techniques, Immunolabeling
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009423 Nervous System Neoplasms Benign and malignant neoplastic processes arising from or involving components of the central, peripheral, and autonomic nervous systems, cranial nerves, and meninges. Included in this category are primary and metastatic nervous system neoplasms. Neoplasms, Nervous System,Nervous System Tumors,Tumors of the Nervous System,Neoplasm, Nervous System,Nervous System Neoplasm,Nervous System Tumor,Tumor, Nervous System,Tumors, Nervous System
D010235 Paraganglioma A neural crest tumor usually derived from the chromoreceptor tissue of a paraganglion, such as the carotid body, or medulla of the adrenal gland (usually called a chromaffinoma or pheochromocytoma). It is more common in women than in men. (Stedman, 25th ed; from Segen, Dictionary of Modern Medicine, 1992) Paraganglioma, Gangliocytic,Paragangliomata,Gangliocytic Paraganglioma,Gangliocytic Paragangliomas,Paragangliomas,Paragangliomatas
D010673 Pheochromocytoma A usually benign, well-encapsulated, lobular, vascular tumor of chromaffin tissue of the ADRENAL MEDULLA or sympathetic paraganglia. The cardinal symptom, reflecting the increased secretion of EPINEPHRINE and NOREPINEPHRINE, is HYPERTENSION, which may be persistent or intermittent. During severe attacks, there may be HEADACHE; SWEATING, palpitation, apprehension, TREMOR; PALLOR or FLUSHING of the face, NAUSEA and VOMITING, pain in the CHEST and ABDOMEN, and paresthesias of the extremities. The incidence of malignancy is as low as 5% but the pathologic distinction between benign and malignant pheochromocytomas is not clear. (Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1298) Pheochromocytoma, Extra-Adrenal,Extra-Adrenal Pheochromocytoma,Extra-Adrenal Pheochromocytomas,Pheochromocytoma, Extra Adrenal,Pheochromocytomas,Pheochromocytomas, Extra-Adrenal
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
Phaeochromocytomas and sympathetic paragangliomas.
December 2009, The British journal of surgery,
M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
Hereditary phaeochromocytomas and paragangliomas: a study of five susceptibility genes.
June 2003, Journal of medical genetics,
M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
[Genetic diagnosis of phaeochromocytomas and paragangliomas].
April 2014, Presse medicale (Paris, France : 1983),
M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
Recognizing hypoxia in phaeochromocytomas and paragangliomas.
April 2020, Nature reviews. Endocrinology,
M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
Phaeochromocytomas and functional paragangliomas: clinical management.
December 2010, Best practice & research. Clinical endocrinology & metabolism,
M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
Predictors of outcome in phaeochromocytomas and paragangliomas.
January 2017, F1000Research,
M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
Potential Pitfalls of SDH Immunohistochemical Detection in Paragangliomas and Phaeochromocytomas Harbouring Germline SDHx Gene Mutation.
February 2017, Anticancer research,
M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
Neurological manifestations of phaeochromocytomas and secretory paragangliomas: a reappraisal.
April 2013, Journal of neurology, neurosurgery, and psychiatry,
M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
New imaging approaches to phaeochromocytomas and paragangliomas.
April 2010, Clinical endocrinology,
M Fraga, and T García-Caballero, and J Antúnez, and M Couce, and A Beiras, and J Forteza
New imaging approaches to phaeochromocytomas and paragangliomas.
February 2010, Clinical endocrinology,
Copied contents to your clipboard!